Signaling Regulatory Protein (SIRP)α-CD47 Blockade Joins the Ranks of Immune Checkpoint Inhibition

Article Tools UNDERSTANDING THE PATHWAY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers. February 27, 2019 ARTICLE CITATION DOI: 10.1200/JCO.19.00121 Journal of Clinical Oncology - published online before print February 27, 2019 PMID: 30811295 Signaling Regulatory Protein (SIRP)α-CD47 Blockade Joins the Ranks of Immune Checkpoint Inhibition André Veillette, MD1,2,3xAndré VeilletteSearch for articles by this author and Zhenghai Tang, PhD1xZhenghai TangSearch for articles by this author Show More 1Institut de Recherches Cliniques de Montréal, Montréal, Quebec, Canada2University of Montréal, Montréal, Quebec, Canada3McGill University, Montréal, Quebec, Canada https://doi.org/10.1200/JCO.19.00121 First Page Full Text PDF Figures and Tables © 2019 by American Society of Clinical Oncology Companion First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers